Chieh-Lung ChengPO-TING YEHFang, Wei-QuanWei-QuanFangWEI-LI MAHSIN-AN HOUCHENG-HONG TSAIHWEI-FANG TIENCHANG-PING LIN2023-01-132023-01-132023-04-052045-7634https://scholars.lib.ntu.edu.tw/handle/123456789/627228The optimal treatment for vitreoretinal lymphoma (VRL) remains a challenge, as central nervous system (CNS) relapse occurs frequently, leading to the worst impact on survival. We previously proposed combined intravitreal methotrexate and systemic high-dose methotrexate therapy for this disease. This study aimed to report the long-term outcomes of patients with VRL using this combination treatment.encombination treatment; methotrexate; relapse; vitreoretinal lymphomajournal article10.1002/cam4.5609366022882-s2.0-85145741328https://api.elsevier.com/content/abstract/scopus_id/85145741328